Increasing Production Carboxymethyl Cellulose and Carboxymethyl Starch and Expansion of Production Capacities to Augment Growth of Monochloroacetic Acid (MCA) Market

 

Monochloroacetic Acid (MCAA) Market

Monochloroacetic acid is an organic compound that is used in chemical synthesis. Agricultural use of phenoxy herbicides and increasing production carboxymethyl cellulose and carboxymethyl starch is expected to boost demand for MCA, thereby propelling growth of the monochloroacetic acid (MCAA) market.  Monochloroacetic acids can be used for numerous purposes. They can be used in the synthesis of rubbers, plastics, dyes, polymers, dyes and enzymes. They are also used in the process of photo-degrowth of materials, photocatalysis and as antimicrobial substances. These chemicals are also used in the synthesis of amino acids, steroids, hormones and enzymes and as plasticizers and stabilizers in various polymers and plastics. Some of the most important polymers where these acids are used include nylon, connector resins, synthetic rubbers, lubricants, polyester, epoxy resins and thermoset polyimide.

Expansion of production capacity is expected to offer lucrative growth opportunities for players in the monochloroacetic acid (MCA) market. For instance, Nouryon announced to expand its production capacity for monochloroacetic acid (MCA) in Delfzijl, the Netherlands by the end of 2020. Similarly, in April 2019, Nouryon completed the expansion at Mahad site (India), which will increase organic chemicals production capacity at the site by 80 percent.

However, release of toxic chemicals and other substances into the air, water and land is expected to hinder growth of the monochloroacetic acid (MCA) market. For instance, according to the U.S. Environmental Protection Agency Toxics Release Inventory, New Jersey companies released over 6 million pounds of toxic chemicals and other substances into the air, water and land in 2018.

Competitive Analysis

Major players operating in the monochloroacetic acid (MCA) market include, AkzoNobel N.V., CABB Group, Nouryon, Nufarm Limited, Niacet Corporation, Jubilant Life Sciences Limited, Shandong Minji Chemical Co., Ltd., Archit Organosys Limited, IOL Chemicals & Pharmaceuticals Limited, Meridian Chem Bond Pvt. Ltd., and S.R. Drugs and Intermediates Pvt. Ltd.

Major players operating in the monochloroacetic acid (MCA) market are focused on expanding production capacity to enhance their market share. For instance, in December 2020, Anaven, a joint venture of Nouryon and Atul, received the environmental clearance for its 32,000 metric tons monochloroacetic acid (MCA) plant in Gujarat, India.

Major players operating in the monochloroacetic acid (MCA) market are also focused on expanding their global presence. For instance, in January 2019, Nouryon started a new headquarters office and research center to support its operations in India.

Location: United States

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more